Sulaiman Nabaa, Fadhul Fadi, Chrcanovic Bruno Ramos
Faculty of Odontology, Malmö University, 214 21 Malmö, Sweden.
Department of Prosthodontics, Faculty of Odontology, Malmö University, 214 21 Malmö, Sweden.
Materials (Basel). 2023 Sep 5;16(18):6078. doi: 10.3390/ma16186078.
The purpose of the present systematic review was to investigate the influence of bisphosphonates (BPs) on the dental implant failure rate and marginal bone loss (MBL). An electronic search was undertaken in three databases, plus a manual search of journals. Meta-analyses were performed, besides a meta-regression in order to verify how the log odds ratio (OR) was associated with follow-up time. The five- and ten-year estimated implant survivals were calculated. The review included 33 publications. Altogether, there were 1727 and 21,986 implants placed in patients taking and not taking BPs, respectively. A pairwise meta-analysis (26 studies) showed that implants in BP patients had a higher failure risk in comparison to non-BP patients (OR 1.653, = 0.047). There was an estimated decrease of 0.004 in log OR for every additional month of follow-up, although it was not significant ( = 0.259). The global estimated implant survival in patients taking BPs after 5 and 10 years was 94.2% (95% CI, 94.0-94.4) and 90.1% (95% CI, 89.8-90.3), respectively. It was not possible to make any reliable analysis concerning MBL, as only two studies reported MBL results separated by groups. There is a 65.3% higher risk of implant failure in patients taking BPs in comparison to patients not taking this class of drugs.
本系统评价的目的是研究双膦酸盐（BPs）对牙种植体失败率和边缘骨丢失（MBL）的影响。在三个数据库中进行了电子检索，并对手工检索了期刊。除了进行Meta回归以验证对数比值比（OR）与随访时间的关系外，还进行了Meta分析。计算了5年和10年的种植体估计生存率。该评价纳入了33篇出版物。总共，分别有1727颗和21986颗种植体植入服用和未服用BPs的患者体内。一项成对Meta分析（26项研究）表明，与未服用BPs的患者相比，服用BPs的患者种植体失败风险更高（OR 1.653，P = 0.047）。随访每增加一个月，对数OR估计下降0.004，尽管不显著（P = 0.259）。服用BPs的患者5年和10年后的总体种植体估计生存率分别为94.2%（95%CI，94.0 - 94.4）和90.1%（95%CI，89.8 - 90.3）。由于只有两项研究按组报告了MBL结果，因此无法对MBL进行任何可靠的分析。与未服用此类药物的患者相比，服用BPs的患者种植体失败风险高65.3%。
